NASDAQ:KIN - Kindred Biosciences, Inc.
$10.81
 $0.34
+3.25%
1:40PM EDT
2019-02-15
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  KIN     avg for
industry  
  avg for
sector  
42 stocks weight:  62. 02   0. 00   0. 00  
42 stocks rank:  2. 44 K 1. 86 K 1. 09 K
# analyst opinions:  5. 00   14. 92   14. 43  
mean recommendation:  2. 00   1. 91   1. 93  

quick ratio:  10. 37   5. 37   1. 81  
current ratio:  10. 82   5. 69   2. 19  

target price low:  19. 00   88. 97   117. 82  
target price avg:  22. 80   115. 19   141. 96  
target price high:  30. 00   143. 40   163. 16  
1-yr high:  15. 50   124. 30   142. 77  
last close:  10. 47   101. 85   127. 84  
50-day avg:  10. 97   98. 27   122. 46  
200-day avg:  12. 05   99. 72   122. 70  
1-yr low:  8. 20   78. 19   100. 16  
volume:  144. 97 K 2. 38 M 4. 64 M
50-day avg volume:  177. 64 K 3. 31 M 4. 94 M
200-day avg volume:  196. 51 K 3. 23 M 4. 28 M

1-day return:  -0. 19 % 0. 22 % 0. 48 %
this week return:  2. 05 % 1. 77 % 2. 01 %
12-wk return:  -18. 71 % 6. 56 % 3. 33 %
52-wk return:  25. 56 % -2. 23 % 14. 35 %

enterprise value (EV):  268. 19 M 55. 17 B 104. 51 B
market cap:  404. 79 M 49. 01 B 96. 46 B
EBITDA:  -44. 65 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -6. 01   -91. 79   2. 29  
enterprise/revenue (EV/R):  419. 05   29. 84   23. 39  
total revenue:  640. 00 K 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -43. 98 M 2. 37 B 3. 58 B

shares outstanding:  38. 66 M 607. 99 M 1. 22 B
shares:  25. 90 M 605. 53 M 1. 15 B
shares short:  420. 63 K 11. 62 M 12. 55 M
shares short prior month:  443. 38 K 11. 95 M 13. 44 M
short ratio:  2. 04   4. 82   3. 10  
short % of float:  2. 05 % 6. 19 % 2. 82 %
total cash/share:  2. 70   12. 02   11. 46  
total cash:  91. 63 M 7. 41 B 7. 37 B
free cash flow:  -29. 48 M 95. 99 M 2. 04 B
operating cash flow:  -37. 94 M 164. 74 M 3. 04 B

book value:  3. 09   14. 43   28. 26  
price/book:  3. 39   -1. 57   -2. 97  
operating margins:  -7086. 72 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  82. 81 % 49. 33 % 54. 53 %

1-yr max volatility:  18. 12 % --- ---
1-yr mean volatility:  0. 12 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 49   3. 03   4. 09  
forward EPS:  -1. 43   4. 33   6. 99  
P/E:  -7. 04   6. 11   26. 91  
forward P/E:  -7. 31   8. 38   10. 48  
PE/G:  0. 81   0. 37   5. 61  
growth:  -8. 69 % 683. 72 % 104. 79 %
earnings high:  -0. 38   1. 27   1. 66  
earnings avg:  -0. 43   1. 01   1. 53  
earnings low:  -0. 51   0. 76   1. 40  
revenue high:  1. 58 M 2. 86 B 11. 19 B
revenue avg:  1. 31 M 2. 78 B 10. 84 B
revenue low:  900. 00 K 2. 67 B 10. 64 B
return on assets:  -26. 99 % -3. 27 % 3. 81 %
return on equity:  -44. 57 % 107. 48 % 27. 82 %
revenue/share:  0. 02   14. 68   59. 83  

beta (1yr vs S&P500):  1. 04   1. 21   0. 93  
sharpe (1yr):  0. 70   0. 06   0. 98  

held % insiders:  6. 00 % 6. 46 % 3. 21 %
held % institutions:  59. 52 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : KIN
.    + 1.748 =         1.748 :: INITIAL WEIGHT
.  + 173.112 =       174.859 :: inverse volume-to-price addition
.  + 479.826 =       654.686 :: spline projection addition
.  - 109.101 =       545.585 :: poor performance penalty
.    x 1.239 =       676.009 :: one-year gains+dividend factor
.    x 4.043 =      2733.424 :: 13 weeks' performance factor
.    x 1.492 =      4079.604 :: industry recommendation factor
.     x 2.16 =      8810.217 :: symbol recommendation factor
.    x 4.876 =     42961.031 :: EV/R factor
.    x 0.997 =     42845.075 :: return on assets factor
.    x 0.996 =     42654.127 :: return on equity factor
.    x 2.099 =       89549.5 :: current ratio factor
.    x 1.052 =     94206.422 :: quick ratio factor
.    x 1.221 =     115001.16 :: short ratio factor
.    x 2.034 =    233901.484 :: price-to-book factor
.     x 2.13 =    498298.781 :: P/E weight
.    x 1.054 =    525369.652 :: PE/G factor
.    x 1.628 =    855473.766 :: beta factor
.    x 0.704 =    601945.182 :: sharpe factor
.    x 1.997 =   1201983.605 :: target low factor
.    x 1.362 =   1636779.552 :: target mean factor
.    x 1.137 =   1860326.102 :: target high factor
.    x 1.066 =   1982387.319 :: industry 12-weeks return
.    x 0.986 =    1955247.68 :: "drift" penalty 2 days ago
.      x 1.0 =   1955071.134 :: overall "drift" factor
.    x 0.819 =   1600903.174 :: largest single-day jump factor
.    x 0.149 =    238584.676 :: low price factor
.      x 1.0 =     238600.69 :: factor hist industry gain for week 06
.   cubeRoot =        62.024 :: reduced for readability
.                     62.024 :: FINAL WEIGHT for NASDAQ:KIN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org